Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Executive Summary

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

You may also be interested in...



Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU

Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.

Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing

Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

Topics

Related Companies

UsernamePublicRestriction

Register

GB001757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel